Comprehensive Analysis of Tumor-Infiltrating Immune Cells and Relevant Therapeutic Strategy in Esophageal Cancer

Dis Markers. 2020 May 11:2020:8974793. doi: 10.1155/2020/8974793. eCollection 2020.

Abstract

A growing body of evidence has indicated that behaviors of cancers are defined by not only intrinsic activities of tumor cells but also tumor-infiltrating immune cells (TIICs) in the tumor microenvironment. However, it still lacks a well-structured and comprehensive analysis of TIICs and its therapeutic value in esophageal cancer (EC). The proportions of 22 TIICs were evaluated between 150 normal tissues and 141 tumor tissues of EC by the CIBERSORT algorithm. Besides, correlation analyses between proportions of TIICs and clinicopathological characters, including age, gender, histologic grade, tumor location, histologic type, LRP1B mutation, TP53 mutation, tumor stage, lymph node stage, and TNM stage, were conducted. We constructed a risk score model to improve prognostic capacity with 5 TIICs by least absolute shrinkage and selection operator (lasso) regression analysis. The risk score = -1.86∗plasma + 2.56∗T cell follicular helper - 1.37∗monocytes - 3.64∗activated dendritic cells - 2.24∗resting mast cells (immune cells in the risk model mean the proportions of immune cell infiltration in EC). Patients in the high-risk group had significantly worse overall survival than these in the low-risk group (HR: 2.146, 95% CI: 1.243-3.705, p = 0.0061). Finally, we identified Semustine and Sirolimus as two candidate compounds for the treatment of EC based on CMap analysis. In conclusion, the proportions of TIICs may be important to the progression, prognosis, and treatment of EC.

MeSH terms

  • Adult
  • Algorithms
  • Antineoplastic Agents / therapeutic use*
  • Cell Count
  • Databases, Factual
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology
  • Dendritic Cells / pathology
  • Esophageal Neoplasms / diagnosis
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / immunology*
  • Esophageal Neoplasms / mortality
  • Female
  • Gene Expression
  • Humans
  • Lymph Nodes / drug effects
  • Lymph Nodes / immunology
  • Lymph Nodes / pathology
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / pathology*
  • Male
  • Mast Cells / drug effects
  • Mast Cells / immunology
  • Mast Cells / pathology
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / immunology
  • Monocytes / pathology
  • Neoplasm Staging
  • Plasma Cells / drug effects
  • Plasma Cells / immunology
  • Plasma Cells / pathology
  • Prognosis
  • Receptors, LDL / genetics
  • Receptors, LDL / immunology
  • Regression Analysis
  • Semustine / therapeutic use
  • Sirolimus / therapeutic use
  • Survival Analysis
  • T Follicular Helper Cells / drug effects
  • T Follicular Helper Cells / immunology
  • T Follicular Helper Cells / pathology
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / genetics
  • Tumor Microenvironment / immunology*
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / immunology

Substances

  • Antineoplastic Agents
  • LRP1B protein, human
  • Receptors, LDL
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Semustine
  • Sirolimus